脉络膜新生血管光动力治疗药物光敏剂的研究进展

doi:10.3969/j.issn.1672-5123.2012.02.17

首页 > 过刊浏览>2012年第12卷第2期 >2012,12(2):249-252. DOI:10.3969/j.issn.1672-5123.2012.02.17

脉络膜新生血管光动力治疗药物光敏剂的研究进展

周晓芳
周晓芳
中国福建省福州市，福建医科大学附属第一医院眼科福建省眼科研究所
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
徐国兴
徐国兴
中国福建省福州市，福建医科大学附属第一医院眼科福建省眼科研究所
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找

Advanced study on the photosensitizer of photodynamic therapy on choroidal neovascularization

Xiao-Fang Zhou
Xiao-Fang Zhou
Department of Ophthalmology,the First Affiliated Hospital of Fujian Medical University, Fujian Institute of Ophthalmology, Fuzhou 350005, Fujian Province, China.
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找
Guo-Xing Xu
Guo-Xing Xu
Department of Ophthalmology,the First Affiliated Hospital of Fujian Medical University, Fujian Institute of Ophthalmology, Fuzhou 350005, Fujian Province, China.
在期刊界中查找
在Google Scholar中查找
在百度中查找
在PubMed中查找
在本站中查找

发布日期：

摘要
图/表
访问统计
PDF预览
参考文献
相似文献
引证文献
附件

[关键词]

光敏剂 ; 脉络膜新生血管 ; 光动力治疗

[摘要]

脉络膜新生血管（choroidal neovascularization, CNV）主要继发于年龄相关性黄斑变性（age-related macular degeneration, AMD），严重影响中心视力，甚至致盲。目前，以光敏剂维替泊芬介导的光动力疗法(photodynamic therapy,PDT)治疗CNV取得了令人瞩目的效果。但由于维替泊芬价格昂贵等问题，临床应用受到一定限制。因此各国的学者均致力于新型光敏剂的研发，以期获得替代维替泊芬的效用，我们就应用于CNV治疗的光敏剂的研究进展作一综述。

[Key word]

photosensitizer ; choroidal neovascularization ; photodynamic therapy

[Abstract]

Choroidal neovascularization (CNV) mainly caused by age-related macular degeneration (AMD), can lead to serious central vision effect, even blindness. At present, the photosensitizer Verteporfin mediated photodynamic therapy(PDT) on CNV achieved remarkable results.Because of the price, the clinical treatment is limited. So the scholars of many countries devoted to the research and development of new photosensitizer to obtain replacement for the utility of Verteporfin, this paper applied to the advanced study on the photosensitizer of PDT on CNV.

[中图分类号]

[基金项目]

中国国家自然科学基金资助项目(No.81070715)；中国卫生部科研基金资助项目（No.WKJ2008-2-61）；中国福建省创新平台基金资助项目（No.2010Y2003）

引用本文 / Get Citation

周晓芳,徐国兴.脉络膜新生血管光动力治疗药物光敏剂的研究进展.国际眼科杂志, 2012,12(2):249-252.

分享 / Share

文章指标 / Article Metrics

点击次数: 1468

下载次数: 1488

Html阅读次数: 0

引用次数: 0

历史 / History

收稿日期: 2011-12-09

最后修改日期: 2012-01-04

1 Zarbin MA.Current concepts in the pathogenesis of age-related macular degeneration. Arch Ophthalmol 2004;22:598-614

2 Dolmans DE, Fukumura D, Jain RK. Photodynamic therapy for cancer. Nat Rev Cancer 2003;3: 380-387

3 Takahashi H, Itoh Y, Miyauchi Y, et al. Activation of two caspase cascades, caspase 8/3/6 and caspase 9/3/6, during photodynamic therapy using a novel photosensitizer, ATX-S10 (Na), in normal human keratinocytes. Arch Dermatol Res 2003;295:242-248

4 Almeida RD, Manadas BJ, Carvalho AP, et al．Intracellular signaling mechanisms in photodynamic therapy. Biochim Biophys Acta 2004;1704(2): 59-86

5 Kessel D, Luguya R, Vicente MG. Localization and photodynamic efficacy of two cationic porphyrins varying in charge distributions. Photochem Photobiol 2003;78:431-435

6 Miller JW，Walsh AW，Krltlller M, et al. Photodynamic therapy of experimental choroidal neovascularization using lipoprotein-derivered benzoporphyrin. Arch Ophthalmol 1995;113:810-818

7 Blinder KJ, Blumenkranz MS, Bressler NM, et al.Verteporfin therapy of subfoveal choroidal neovascularization pathologic myopia:2-year results of randomized clinical trial-VIP no. 3. Ophthalmology 2003;110:667-673

8 Blumenkranz MS, Bressler NM, Bressler SB, et al.Verteporfin therapy for subfoveal choroidal neovascularization in age-related macular degeneration:three-year results of an open-label extension of 2 randomized clinical trials-TAP Report 5. Arch Ophthalmol 2002;120:1307-1314

9 Schmidt-Erfurth U,Schlotzer-Schrehard U, Cursiefen C, et al. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003;44(10):4473-4480

10 Michels S,Hansmann F,Geitzenauer W, et al.Influence of treatment parameters on selectivity of veterporfin therapy. Invest Ophthalmol Vis Sci 2006;47:371-376

11 Dhalla MS, Shan GK,Blinder KJ. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retinal 2006;26:988-993

12 Peyman GA, Moshfeghi DM, Moshfeghi A, et al. Photodynamic therapy for choriocapillaris using tin ethyl etiopurpurin(SnET2). Ophthalmic Surg Lasers 1997;28(5):409-417

13 Mori K, Kanai K, Peyman GA, et al. Intraocular biodistribution of mono-L-aspartyl chlorin e6 in a primate choroidal neovascularization model. Ophthalmic Surg Lasers Imaging 2007;38(2):142-147

14 Blumenkranz MS, Woodburn KW,Qing F, et al. Lutetium Texaphyrin (Lu-Tex): A Potential New Agent for Ocular Fundus Angiography and Photodynamic Therapy. Am J Ophthalmol 2000;129(3):353-362

15 Renno RZ, Delori FC, Holzer RA, et al. Photodynamic Therapy Using Lu-Tex Induces Apoptosis In Vitro, and Its Effect Is Potentiated by Angiostatin in Retinal Capillary Endothelial Cells. Invest Ophthalmol Vis Sci 2000;41(12):3963-3971

16 Dolmans DE,Kadambi A,Hill JS, et al. Vascular Accumulation of a Novel Photosensitizer, MV6401, Causes Selective Thrombosis in Tumor Vessels after Photodynamic Therapy. Cancer Res 2002;62:2151-2156

17 Ciulla TA, Criswell MH, Snyder WJ, et al. Photodynamic therapy with PhotoPoint photosensitiser MV6401, indium chloride methyl pyropheophorbide,achieves selective closure of rat corneal neovascularisation and rabbit choriocapillaris. Br J Ophthalmol 2005;89:113-119

18 Ciulla TA, Criswell MH, Danis RP, et al. Evaluation of photopoint photosensitizer mv6401, indium chloride methyl pyropheophorbide, as a photodynamic therapy agent in primate choriocapillaris and laser-induced choroidal neovascularization. Retina 2004;24(4):521-529

19 Miller JD, Baron ED, Scull H, et al.Photodynamic therapy with the phthalocyanine photosensitizer Pc4:The case experience with preclinical mechanistic and early clinical-translational studies. Toxicol Appl Pharmacol 2007;224(3):290-299

20 Huang Y, Xu G, Peng Y, et al. Zinc phthalocyanine tetrasulfonate (ZnPcS4): a new photosensitizer for photodynamic therapy in choroidal neovascularization. J Ocul Pharmacol Ther 2007;23(4):377-386

21 Huang Y, Xu GX, Peng YR, et al. Photodynamic effects of ZnPcS4-BSA in human retinal pigment epithelium cells. J Ocul Pharmacol Ther 2009;25(3): 231-238

22 Nishiyama N, Morimoto Y, Jang WD, et al. Design and development of dendrimer photosensitizer-incorporated polymeric micelles for enhanced photodynamic therapy. Adv Drug Deliv Rev 2009;61（4）:327-338

23 魏玉德.竹红菌素研究的进展.中国实用医药 2008;3(11):147-149

24 Fei XF, Chen J, Zheng KY, et al. Apoptotic effects of hypocrellin A on HeLa cells. Chem Res Chinese U 2006,22(6): 772-775